Considering that TGM2 is the primary enzyme involved in the aggregation of toxic peptides linked to these NDDs, it follows that it should be considered a primary and almost universal therapeutic target for NDD treatments. The gene discussed is TGM2; the disease is Neurodevelopmental delay.